{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T14:40:32Z","timestamp":1734792032990,"version":"3.32.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,21]]},"DOI":"10.7759\/cureus.76132","type":"journal-article","created":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T13:59:06Z","timestamp":1734789546000},"source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of Risk Factors for Dupilumab-Associated Ocular Sequelae in the Treatment of Atopic Dermatitis"],"prefix":"10.7759","author":[{"given":"Varsha","family":"Reddy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexa","family":"Lum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katerina","family":"Kitsios","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swarna","family":"Shil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alanna","family":"Nattis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31286-1","article-title":"Atopic dermatitis","volume":"396","author":"Langan SM","year":"2020","unstructured":"Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020, 396:345-60. 10.1016\/S0140-6736(20)31286-1","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.12.022","article-title":"Dupilumab: a review of its use in the treatment of atopic dermatitis","volume":"78","author":"Gooderham MJ","year":"2018","unstructured":"Gooderham MJ, Hong HC, Eshtiaghi P, Papp KA. Dupilumab: a review of its use in the treatment of atopic dermatitis. J Am Acad Dermatol. 2018, 78:S28-36. 10.1016\/j.jaad.2017.12.022","journal-title":"J Am Acad Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.08.022","article-title":"Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis","volume":"143","author":"Guttman-Yassky E","year":"2019","unstructured":"Guttman-Yassky E, Bissonnette R, Ungar B, et al.. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol. 2019, 143:155-72. 10.1016\/j.jaci.2018.08.022","journal-title":"J Allergy Clin Immunol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/cea.13491","article-title":"Mechanisms of dupilumab","volume":"50","author":"Harb H","year":"2020","unstructured":"Harb H, Chatila TA. Mechanisms of dupilumab. Clin Exp Allergy. 2020, 50:5-14. 10.1111\/cea.13491","journal-title":"Clin Exp Allergy"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2022.02.002","article-title":"Dupilumab-associated ocular manifestations: a review of clinical presentations and management","volume":"67","author":"Wu D","year":"2022","unstructured":"Wu D, Daniel BS, Lai AJ, et al.. Dupilumab-associated ocular manifestations: a review of clinical presentations and management. Surv Ophthalmol. 2022, 67:1419-42. 10.1016\/j.survophthal.2022.02.002","journal-title":"Surv Ophthalmol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1080\/1364557032000119616","article-title":"Scoping studies: towards a methodological framework","volume":"8","author":"Arksey H","year":"2005","unstructured":"Arksey H, O'Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2005, 8:19-32. 10.1080\/1364557032000119616","journal-title":"Int J Soc Res Methodol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.11124\/JBIES-20-00167","article-title":"Updated methodological guidance for the conduct of scoping reviews","volume":"18","author":"Peters MD","year":"2020","unstructured":"Peters MD, Marnie C, Tricco AC, et al.. Updated methodological guidance for the conduct of scoping reviews. JBI Evid Synth. 2020, 18:2119-26. 10.11124\/JBIES-20-00167","journal-title":"JBI Evid Synth"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.46658\/JBIMES-24-09","article-title":"Scoping reviews","author":"Peters MD","year":"2024","unstructured":"Peters MD, Godfrey C, McInerney P, Munn Z, Tricco AC, Khalil H. Scoping reviews. JBI Manual for Evidence Synthesis. Aromataris E, Lockwood C, Porritt K, Pilla B, Jordan Z (ed): JBI, 2024. 10.46658\/JBIMES-24-09"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v102.1128","article-title":"Identification of risk factors for dupilumab-associated ocular surface disease in patients with atopic dermatitis","volume":"102","author":"Achten RE","year":"2022","unstructured":"Achten RE, Van Luijk C, Van der Rijst L, et al.. Identification of risk factors for dupilumab-associated ocular surface disease in patients with atopic dermatitis. Acta Derm Venereol. 2022, 102:adv00666. 10.2340\/actadv.v102.1128","journal-title":"Acta Derm Venereol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16724","article-title":"Incidence and risk factors for dupilumab associated ocular adverse events: a real-life prospective study","volume":"35","author":"Touhouche AT","year":"2021","unstructured":"Touhouche AT, Cassagne M, B\u00e9rard E, et al.. Incidence and risk factors for dupilumab associated ocular adverse events: a real-life prospective study. J Eur Acad Dermatol Venereol. 2021, 35:172-9. 10.1111\/jdv.16724","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1177\/11206721231199155","article-title":"Dupilumab induced ocular surface disease: a prospective case series","volume":"34","author":"Pradhan SP","year":"2024","unstructured":"Pradhan SP, Sadiq SN, Cartes C, et al.. Dupilumab induced ocular surface disease: a prospective case series. Eur J Ophthalmol. 2024, 34:691-9. 10.1177\/11206721231199155","journal-title":"Eur J Ophthalmol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2019-315010","article-title":"Dupilumab-induced ocular surface disease (DIOSD) in patients with atopic dermatitis: clinical presentation, risk factors for development and outcomes of treatment with tacrolimus ointment","volume":"104","author":"Nahum Y","year":"2020","unstructured":"Nahum Y, Mimouni M, Livny E, Bahar I, Hodak E, Leshem YA. Dupilumab-induced ocular surface disease (DIOSD) in patients with atopic dermatitis: clinical presentation, risk factors for development and outcomes of treatment with tacrolimus ointment. Br J Ophthalmol. 2020, 104:776-9. 10.1136\/bjophthalmol-2019-315010","journal-title":"Br J Ophthalmol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.18176\/jiaci.0481","article-title":"Dupilumab-associated conjunctivitis in patients with atopic dermatitis: a multicenter real-life experience","volume":"30","author":"Nettis E","year":"2020","unstructured":"Nettis E, Bonzano L, Patella V, Detoraki A, Trerotoli P, Lombardo C. Dupilumab-associated conjunctivitis in patients with atopic dermatitis: a multicenter real-life experience. J Investig Allergol Clin Immunol. 2020, 30:201-4. 10.18176\/jiaci.0481","journal-title":"J Investig Allergol Clin Immunol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.2690","article-title":"Risk factors for dupilumab-associated conjunctivitis in patients with atopic dermatitis","volume":"154","author":"Treister AD","year":"2018","unstructured":"Treister AD, Kraff-Cooper C, Lio PA. Risk factors for dupilumab-associated conjunctivitis in patients with atopic dermatitis. JAMA Dermatol. 2018, 154:1208-11. 10.1001\/jamadermatol.2018.2690","journal-title":"JAMA Dermatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.15584","article-title":"Prevalence of ocular disease during dupilumab treatment for atopic dermatitis: a bicentric retrospective comparative cohort study","volume":"60","author":"Barb\u00e9 J","year":"2021","unstructured":"Barb\u00e9 J, Poreaux C, Remen T, et al.. Prevalence of ocular disease during dupilumab treatment for atopic dermatitis: a bicentric retrospective comparative cohort study. Int J Dermatol. 2021, 60:1520-8. 10.1111\/ijd.15584","journal-title":"Int J Dermatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.12.039","article-title":"Conjunctivitis in patients with atopic dermatitis treated with dupilumab is associated with higher baseline serum levels of immunoglobulin E and thymus and activation-regulated chemokine but not clinical severity in a real-world setting","volume":"82","author":"Uchida H","year":"2020","unstructured":"Uchida H, Kamata M, Nagata M, et al.. Conjunctivitis in patients with atopic dermatitis treated with dupilumab is associated with higher baseline serum levels of immunoglobulin E and thymus and activation-regulated chemokine but not clinical severity in a real-world setting. J Am Acad Dermatol. 2020, 82:1247-9. 10.1016\/j.jaad.2019.12.039","journal-title":"J Am Acad Dermatol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18932","article-title":"Multicenter prospective observational study of dupilumab-induced ocular events in atopic dermatitis patients","volume":"37","author":"Costedoat I","year":"2023","unstructured":"Costedoat I, Wallaert M, Gaultier A, et al.. Multicenter prospective observational study of dupilumab-induced ocular events in atopic dermatitis patients. J Eur Acad Dermatol Venereol. 2023, 37:1056-63. 10.1111\/jdv.18932","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-019-0191-9","article-title":"Ocular surface diseases induced by dupilumab in severe atopic dermatitis","volume":"8","author":"Maudinet A","year":"2019","unstructured":"Maudinet A, Law-Koune S, Duretz C, Lasek A, Modiano P, Tran TH. Ocular surface diseases induced by dupilumab in severe atopic dermatitis. Ophthalmol Ther. 2019, 8:485-90. 10.1007\/s40123-019-0191-9","journal-title":"Ophthalmol Ther"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17869","article-title":"Conjunctivitis in dupilumab clinical trials","volume":"181","author":"Akinlade B","year":"2019","unstructured":"Akinlade B, Guttman-Yassky E, de Bruin-Weller M, et al.. Conjunctivitis in dupilumab clinical trials. Br J Dermatol. 2019, 181:459-73. 10.1111\/bjd.17869","journal-title":"Br J Dermatol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2020.09.042","article-title":"Long-term follow-up and treatment outcomes of conjunctivitis during dupilumab treatment in patients with moderate-to-severe atopic dermatitis","volume":"9","author":"Achten R","year":"2021","unstructured":"Achten R, Bakker D, Ariens L, et al.. Long-term follow-up and treatment outcomes of conjunctivitis during dupilumab treatment in patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol Pract. 2021, 9:1389-1392.e2. 10.1016\/j.jaip.2020.09.042","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/cea.14461","article-title":"Ocular surface disease in moderate-to-severe atopic dermatitis patients and the effect of biological therapy","volume":"54","author":"Achten R","year":"2024","unstructured":"Achten R, Thijs J, van der Wal M, et al.. Ocular surface disease in moderate-to-severe atopic dermatitis patients and the effect of biological therapy. Clin Exp Allergy. 2024, 54:241-52. 10.1111\/cea.14461","journal-title":"Clin Exp Allergy"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/285541-evaluation-of-risk-factors-for-dupilumab-associated-ocular-sequelae-in-the-treatment-of-atopic-dermatitis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T13:59:07Z","timestamp":1734789547000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/285541-evaluation-of-risk-factors-for-dupilumab-associated-ocular-sequelae-in-the-treatment-of-atopic-dermatitis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,21]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.76132","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,21]]}}}